MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by PETRACK, B.
Right arrow Articles by CZERNIK, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PETRACK, B.
Right arrow Articles by CZERNIK, A. J.

Molecular Pharmacology, Vol 12, 203-207, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics

Inhibition of Isoproterenol Activation of Adenylate Cyclase by Metoprolol, Oxprenolol, and the para Isomer of Oxprenolol

BARBARA PETRACK 1 and ANDREW J. CZERNIK 1

1 Research Department, Pharmaceuticals Division, Ciba-Geigy Corporation, Ardsley, New York 10502

The beta adrenergic blocking agents metoprolol, oxprenolol, and the para isomer of oxprenolol were evaluated as inhibitors of isoproterenol activation of adenylate cyclase (EC 4.6.1.1) in membrane preparations from dog heart and liver. Metoprolol, like practolol, was selective, since both drugs inhibited activation of the heart enzyme 10 times more effectively than the liver enzyme. However, metoprolol was considerably more potent than practolol, although it was less active than propranolol. Oxprenolol was a highly effective inhibitor in these systems, comparable in potency to propranolol. Oxprenolol, like propranolol, was a nonspecific beta blocker, since these drugs inhibited both heart and liver enzyme systems with the same potency. In contrast, the para isomer of oxprenolol was beta1 selective, although it was considerably less potent than oxprenolol. The biochemical data are consistent with the pharmacological effects of these drugs and add further support to the proposed role of the adenylate cyclase system in the molecular mechanisms associated with beta adrenergic stimulation and inhibition.

Note:
ACKNOWLEDGMENT We would like to express our appreciation to Dr. William D. Cash for valuable advice during the course of this work.

Submitted on September 12, 1975







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics